diff --git a/.last-update.json b/.last-update.json index 19755ea..24630a3 100644 --- a/.last-update.json +++ b/.last-update.json @@ -1,5 +1,5 @@ { - "updatedAt": "2026-08-30T18:18:56.213Z", + "updatedAt": "2026-08-31T18:24:33.209Z", "command": "update", "model": "MiniMax-M3", "status": "complete", diff --git a/commitments.md b/commitments.md index 90bd731..3e83a20 100644 --- a/commitments.md +++ b/commitments.md @@ -2,8 +2,8 @@ type: "Reference" title: "Commitments" description: "Active work tasks, follow-ups, approvals, and scheduled items extracted from sources (web-search, git-repo, literature flywheel-sync, etc.). Personal errands live in /personal-logistics.md instead." -tags: [commitments, work, follow-ups, distributors-2026-08-07-refresh, dong-huiqun-ji-nan-chengquan-link, liang-2026-celvivo-clinostar-positioning, guo-2026-organoid-irb-checklist-rollout, celvivo-app-note-2026-clinostar-vs-orbital-shaker-positioning, aiello-2025-rc-cfd-clinostar-positioning, kim-2025-egain-3d-mea-vs-3brain-positioning, ajongbolo-2025-brain-organoid-review-cluster, tian-2025-epicardium-mtor-cardiac-expansion, tevonian-2026-vascularized-liver-mps-positioning, yang-2026-cardiac-organoid-review-positioning, shen-2026-vascularized-organoid-chinese-review, zhai-2026-skin-organoid-pemphigus-positioning, 2026-08-25] -timestamp: 2026-08-25T18:13:00Z +tags: [commitments, work, follow-ups, distributors-2026-08-07-refresh, dong-huiqun-ji-nan-chengquan-link, liang-2026-celvivo-clinostar-positioning, guo-2026-organoid-irb-checklist-rollout, celvivo-app-note-2026-clinostar-vs-orbital-shaker-positioning, aiello-2025-rc-cfd-clinostar-positioning, kim-2025-egain-3d-mea-vs-3brain-positioning, ajongbolo-2025-brain-organoid-review-cluster, tian-2025-epicardium-mtor-cardiac-expansion, tevonian-2026-vascularized-liver-mps-positioning, yang-2026-cardiac-organoid-review-positioning, shen-2026-vascularized-organoid-chinese-review, zhai-2026-skin-organoid-pemphigus-positioning, stewart-2023-ba5-xbb-neurotropic-brain-organoid, aiello-2025-brain-organoid-reproducibility-celvivo, nguyen-2024-jev-g4-australia-brain-organoid, miao-2025-vascularized-lung-gut-celvivo, yan-2024-tmem106b-sars-cov2-brain-organoid, 2026-08-31, 2026-08-25] +timestamp: 2026-08-31T18:09:00Z --- # Commitments @@ -187,6 +187,41 @@ Concrete work tasks, follow-ups, approvals, and scheduled items extracted from G - Status: open - Notes: **First 3D-skin organoid disease-modeling paper** in Robin's deep-read set; **net-new application domain** (autoimmune dermatology + 3D skin) that Robin's existing ~22 deep-read subfolders do not cover. Uses **3D 打印 + 自组织多层血管化皮肤模型** to model 天疱疮 (pemphigus) autoimmune disease + EGFR 靶向治疗 + ML 辅助药筛. **Vendor anchor mapping**: TBD — Zhai paper does NOT have the `9aa2af4c` retrofit 5-vendor mapping (only Tevonian + Yang got the retrofit). Skin organoid is a candidate workflow for **CelVivo ClinoReactor** (long-term 3D skin culture — similar to the existing liver, brain, lung, retinal organoid applications) but the Sci Adv paper's specific ClinoReactor / ClinoStar callouts are not in the manifest entry. **Application domain**: 3D skin organoid + autoimmune dermatology (pemphigus) — distinct from the existing Cancer / Brain / Liver / Vascularized-Organoids / Cardiac-Organoids / Kidney / Retinal / Brain-Tumor application-domain subfolders. **Robin 业务对接**: 皮肤自身免疫病药筛 + 3D 打印客户 + 精准医疗应用. Follow-ups: (a) add a wiki-side deep-read synthesis page at `/sources/literature-zhai-2026-sciadv-3d-skin-pemphigus-deepread.md`; (b) verify whether the Skin-Organoids subfolder accumulates ≥3 entries to confirm a recurring application-domain pattern; (c) check whether the Zhai paper yields Chinese cosmetic / dermatology pharma R&D positioning material that the active CRM portfolio could absorb. +### stewart-2023-ba5-xbb-neurotropic-brain-organoid: Stewart 2023 Front Microbiol BA.5/XBB neurotropic brain organoid CelVivo viral-pathology positioning +- Owner: me +- Source: git-repo-1 2026-08-31 — vault commit `eb24ab72` (Stewart R et al. Front Microbiol 2023 SARS-CoV-2 omicron BA.5/XBB neurotropic brain organoids, DOI 10.3389/fmicb.2023.1320856; vault path `obsidian-vault/04-Literature/Deep-Reads/CelVivo/stewart-2023-ba5-xbb-neurotropic-brain-organoids.md`, **first file in NEW `CelVivo/` (capital-V) parallel subfolder** at `obsidian-vault/04-Literature/Deep-Reads/CelVivo/`; QIMR Berghofer Medical Research Institute + University of Queensland) +- Due: unscheduled +- Status: open +- Notes: **First file in NEW `CelVivo/` (capital-V) parallel subfolder** — Robin's first parallel-naming deep-read subfolder convention (parallel to existing lowercase `Celvivo/` 142-file subfolder). BA.5/XBB variants have increased neurotropic potential vs BA.1 in K18-hACE2 mice + human brain organoids. **Vendor anchor mapping**: CelVivo ClinoStar (direct platform) — the paper uses CelVivo ClinoStar brain organoid platform for the SARS-CoV-2 BA.5/XBB infection model; supports Robin's CelVivo ClinoStar ⭐⭐⭐⭐⭐ positioning for brain organoid viral-pathology applications (脑类器官病毒感染 + 神经嗜性研究). Companion to the Yan 2024 + Nguyen 2024 brain-organoid infectious-disease papers from the same 2026-08-31 cluster — all 3 are QIMR Berghofer Suhrbier/Rawle viral-neurotropism line. Follow-ups: (a) add a wiki-side deep-read synthesis page at `/sources/literature-stewart-2023-front-microbiol-ba5-xbb-neurotropic-brain-organoids-deepread.md`; (b) bundle Stewart + Yan + Nguyen as the QIMR Berghofer Suhrbier/Rawle viral-neurotropism brain-organoid trio on `/themes/05-robin-research.md`; (c) verify whether the Stewart paper yields Chinese pharma R&D / CDMO viral-pathology positioning material (COVID-19 长期后遗症 + 神经嗜性变异株 screening). + +### aiello-2025-brain-organoid-reproducibility-celvivo: Aiello 2025 EMBO reports brain organoid reproducibility — CelVivo ApS co-authored platform standard +- Owner: me +- Source: git-repo-1 2026-08-31 — vault commit `030f31ed` (Aiello G, Nemir M, Vidimova B et al. EMBO reports 2025 Increased reproducibility of brain organoids through controlled fluid dynamics, DOI 10.1038/s44319-025-00619-x; vault path `obsidian-vault/04-Literature/Deep-Reads/CelVivo/aiello-2025-brain-organoid-reproducibility.md`; **CelVivo ApS (丹麦) is a co-author affiliation** + 洛桑大学 + 罗马 Tor Vergata 大学 + 西北大学(南非)) +- Due: unscheduled +- Status: open +- Notes: **CelVivo ApS is a co-author affiliation** — first Robin deep-read paper with CelVivo ApS as a direct co-author (vs prior papers that mention CelVivo ClinoStar/ClinoReactor but CelVivo ApS is not on the author list). The paper establishes that **controlled fluid dynamics (ClinoStar/ClinoReactor) produces CV <15% morphological consistency** vs static culture CV >30% across multi-batch + multi-iPSC-line brain organoid cultures + SOX2/Nestin/PAX6 + DCX + TBR1/SATB2/MAP2 multi-marker IHC recapitulation + scRNA-seq OXPHOS metabolic profiling. **Vendor anchor mapping**: **CelVivo ClinoStar ⭐⭐⭐⭐⭐** (direct platform validation as a reproducibility-benchmarking standard; the paper IS the canonical ClinoStar/ClinoReactor platform standard for any Chinese brain organoid customer) + 3Brain HD-MEA-adjacent (cortical organoid electrophysiology read-out). **Robin 业务对接**: brain organoid reproducibility standard for 三甲医院 / 中国脑科学客户 + CDMO brain organoid manufacturing benchmark + multi-iPSC-line cross-validation reference. Follow-ups: (a) add a wiki-side deep-read synthesis page at `/sources/literature-aiello-2025-embo-reports-brain-organoid-reproducibility-deepread.md`; (b) cross-link Aiello with the existing `aiello-bagni-2025-rc-cfd-clinostar-positioning` commitment from the 2026-08-23/24 cluster (same authors + same paper, but the 2026-08-23/24 entry was a biorxiv preprint and the 2026-08-31 entry is the EMBO reports published version — pair as pre-print + published); (c) cross-link Aiello with the existing `class-organoid-3d-bioprinting` theme row at `/themes.md` as the brain-organoid reproducibility reference. + +### nguyen-2024-jev-g4-australia-brain-organoid: Nguyen 2024 npj Viruses JEV G4 2022 Australia brain organoid viral-pathology positioning +- Owner: me +- Source: git-repo-1 2026-08-31 — vault commit `fad7e21e` (Nguyen W et al. npj Viruses 2024 Characterisation of a Japanese Encephalitis virus genotype 4 isolate from the 2022 Australian outbreak, DOI 10.1038/s44298-024-00025-5; vault path `obsidian-vault/04-Literature/Deep-Reads/CelVivo/nguyen-2024-jev-g4-2022-australia-brain-organoids.md`; QIMR Berghofer Medical Research Institute + INRAE) +- Due: unscheduled +- Status: open +- Notes: **JEV genotype 4 isolate characterization** using human brain organoids (CelVivo ClinoStar) + mouse model. The paper extends the QIMR Berghofer Suhrbier/Rawle viral-neurotropism brain-organoid line into the flavivirus (JEV) application domain — distinct from the SARS-CoV-2 BA.5/XBB (Stewart 2023) + TMEM106B SARS-CoV-2 (Yan 2024) papers in the same cluster. **Vendor anchor mapping**: CelVivo ClinoStar (direct platform) — supports Robin's CelVivo ClinoStar ⭐⭐⭐⭐ positioning for brain organoid viral-pathology applications in flavivirus / JEV research (Japanese encephalitis is endemic in 东南亚 + 中国南方 + 西太平洋 — directly relevant to Chinese infectious-disease R&D customer base). **Robin 业务对接**: 虫媒病毒 (JEV / Zika / dengue) 神经嗜性研究 + 疫苗开发 + 抗病毒药筛. Follow-ups: (a) add a wiki-side deep-read synthesis page at `/sources/literature-nguyen-2024-npj-viruses-jev-g4-brain-organoids-deepread.md`; (b) bundle Nguyen with Stewart + Yan as the QIMR Berghofer Suhrbier/Rawle viral-neurotropism brain-organoid trio on `/themes/05-robin-research.md`; (c) verify whether the JEV/flavivirus application domain yields Chinese pharma R&D / CDMO positioning material (active CRM profile set is mostly CelVivo / 3Brain neural-organoid focused — no flavivirus customer dossier surfaced yet). + +### miao-2025-vascularized-lung-gut-celvivo: Miao 2025 Cell vascularized lung/gut organoids — CelVivo ClinoReactor co-differentiation platform +- Owner: me +- Source: git-repo-1 2026-08-31 — vault commit `4fca0123` (Miao Y et al. Cell 2025 Co-development of mesoderm and endoderm enables organotypic vascularization in lung and gut organoids, DOI 10.1016/j.cell.2025.05.041; vault path `obsidian-vault/04-Literature/Deep-Reads/CelVivo/miao-2025-vascularized-lung-gut-organoids.md`) +- Due: unscheduled +- Status: open +- Notes: **Miao 2025 v1 (Cell published version, 8-08 精简版已升级完整版)** — companion to the 2026-08-08 flywheel-sync Miao 2025 v2 deep-read that already exists in Robin's vault as `/home/ldw/workspace/Miao2025_Cell_v2.md`. The Cell published version (this commit) extends the v2 deep-read with the canonical CelVivo ClinoReactor co-differentiation mesoderm+endoderm platform for **organotypic vascularization in lung and gut organoids**. **Vendor anchor mapping**: **CelVivo ClinoReactor ⭐⭐⭐⭐⭐** (direct platform validation as the co-differentiation + vascularization standard; the paper IS the canonical ClinoReactor lung/gut vascularization standard) + scRNA-seq single-cell profiling of FOXF1 endothelial-mesenchymal transition. **Robin 业务对接**: lung organoid + gut organoid + vascularization + 呼吸道病毒 / 肠道病毒感染模型 + 中国肺纤维化 / IBD pharma R&D positioning. Follow-ups: (a) add a wiki-side deep-read synthesis page at `/sources/literature-miao-2025-cell-vascularized-lung-gut-organoids-celvivo-deepread.md` (separate from the existing `/sources/literature-miao-2025-cell-vascularization-v2-deepread.md` which is the 2026-08-08 flywheel-sync synthesis); (b) cross-link Miao 2025 v1 (this commit, in `CelVivo/` capital-V subfolder) with Miao 2025 v2 (the 2026-08-08 flywheel-sync, in vault root) on `/sources/literature.md`; (c) verify whether the lung/gut vascularization application domain yields Chinese pharma R&D positioning material for respiratory / IBD CDMO accounts. + +### yan-2024-tmem106b-sars-cov2-brain-organoid: Yan 2024 Cell Reports TMEM106B SARS-CoV-2 ACE2-independent brain organoid viral-entry positioning +- Owner: me +- Source: git-repo-1 2026-08-31 — vault commit `391e4713` (Yan K, Dumenil T, Stewart R et al. Cell Reports 2024 TMEM106B-mediated SARS-CoV-2 infection allows for robust ACE2-independent infection in vitro but not in vivo, DOI 10.1016/j.celrep.2024.114921; vault path `obsidian-vault/04-Literature/Deep-Reads/CelVivo/yan-2024-tmem106b-sars-cov2-ace2-independent.md`; QIMR Berghofer Medical Research Institute) +- Due: unscheduled +- Status: open +- Notes: **CRISPR 筛选鉴定 TMEM106B/硫酸乙酰肝素/内吞介导 ACE2 非依赖进入** in human cortical brain organoids (CelVivo ClinoStar) — establishes a novel ACE2-independent SARS-CoV-2 viral entry pathway. **In vitro vs in vivo discrepancy** — MA1 has stronger neurotropism in vitro brain organoids but does not increase neuroinvasion in wild-type / Ifnar-/- mice; Ace2-/- mice cannot be infected via lung. **Vendor anchor mapping**: CelVivo ClinoStar (direct platform) — supports Robin's CelVivo ClinoStar ⭐⭐⭐⭐ positioning for brain organoid viral-entry-mechanism research (SARS-CoV-2 TMEM106B / 硫酸乙酰肝素 / 内吞介导). Companion to Stewart 2023 (BA.5/XBB) + Nguyen 2024 (JEV G4) in the QIMR Berghofer Suhrbier/Rawle viral-neurotropism trio. **Robin 业务对接**: viral entry mechanism + 抗病毒药筛 + brain organoid platform validation. Follow-ups: (a) add a wiki-side deep-read synthesis page at `/sources/literature-yan-2024-cell-reports-tmem106b-sars-cov2-brain-organoids-deepread.md`; (b) bundle Yan with Stewart + Nguyen as the QIMR Berghofer Suhrbier/Rawle viral-neurotropism brain-organoid trio on `/themes/05-robin-research.md`; (c) verify whether the TMEM106B / 硫酸乙酰肝素 viral-entry-mechanism research yields Chinese pharma R&D / CDMO positioning material for ACE2-independent antiviral drug screening. +